1. Home
  2. TSHA vs CET Comparison

TSHA vs CET Comparison

Compare TSHA & CET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TSHA
  • CET
  • Stock Information
  • Founded
  • TSHA 2019
  • CET 1929
  • Country
  • TSHA United States
  • CET United States
  • Employees
  • TSHA N/A
  • CET N/A
  • Industry
  • TSHA Biotechnology: Pharmaceutical Preparations
  • CET Finance/Investors Services
  • Sector
  • TSHA Health Care
  • CET Finance
  • Exchange
  • TSHA Nasdaq
  • CET Nasdaq
  • Market Cap
  • TSHA 1.4B
  • CET 1.5B
  • IPO Year
  • TSHA 2020
  • CET N/A
  • Fundamental
  • Price
  • TSHA $4.72
  • CET $50.60
  • Analyst Decision
  • TSHA Strong Buy
  • CET
  • Analyst Count
  • TSHA 8
  • CET 0
  • Target Price
  • TSHA $9.63
  • CET N/A
  • AVG Volume (30 Days)
  • TSHA 11.3M
  • CET 33.8K
  • Earning Date
  • TSHA 11-12-2025
  • CET 01-01-0001
  • Dividend Yield
  • TSHA N/A
  • CET 4.58%
  • EPS Growth
  • TSHA N/A
  • CET N/A
  • EPS
  • TSHA N/A
  • CET 7.40
  • Revenue
  • TSHA $8,098,000.00
  • CET $27,062,484.00
  • Revenue This Year
  • TSHA N/A
  • CET N/A
  • Revenue Next Year
  • TSHA N/A
  • CET N/A
  • P/E Ratio
  • TSHA N/A
  • CET $6.78
  • Revenue Growth
  • TSHA N/A
  • CET 15.78
  • 52 Week Low
  • TSHA $1.05
  • CET $40.24
  • 52 Week High
  • TSHA $5.51
  • CET $52.42
  • Technical
  • Relative Strength Index (RSI)
  • TSHA 59.56
  • CET 45.80
  • Support Level
  • TSHA $4.80
  • CET $50.63
  • Resistance Level
  • TSHA $5.51
  • CET $51.91
  • Average True Range (ATR)
  • TSHA 0.44
  • CET 0.85
  • MACD
  • TSHA 0.04
  • CET -0.19
  • Stochastic Oscillator
  • TSHA 66.02
  • CET 20.95

About TSHA Taysha Gene Therapies Inc.

Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.

About CET Central Securities Corporation

Central Securities Corp is a non-diversified closed-end management investment company. Its investment objective is long-term growth of capital. The company invests in common stocks, bonds, convertible bonds, preferred stocks, convertible preferred stocks, warrants, options real estate, or short-term obligations of governments, banks, and corporations.

Share on Social Networks: